Publisher: Sanofi-aventis Israel ltd, P.O.B. 8090 Netanya 4250499
ROVAMYCIN.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. |
Active ingredient: each tablet contains 1.5 MIU Spiramycin.
Excipients: Microcrystalline cellulose, Gelifiable maize starch, Hydroxypropylcellulose, Sodium croscarmellose, Hypromellose, Magnesium stearate, Macrogol 6000, Titanium dioxide, Anhydrous colloidal silica.
| Active Ingredient | Description | |
|---|---|---|
| Spiramycin |
Antibacterial antibiotic belonging to the macrolides family. Spiramycin inhibits translocation by binding to bacterial 50S ribosomal subunits with an apparent 1:1 stoichiometry. This antibiotic is a potent inhibitor of the binding to the ribosome of both donor and acceptor substrates. Spiramycin induces rapid breakdown of polyribosomes, an effect which has formerly been interpreted as occurring by normal ribosomal run-off followed by an antibiotic-induced block at or shortly after initiation of a new peptide. |
| List of Excipients |
|---|
|
|
Sanofi-aventis Israel ltd, P.O.B. 8090 Netanya 4250499
| Drug | Countries | |
|---|---|---|
| ROVAMYCIN | Canada, Israel |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
